Aytu BioPharma, Inc. (AYTU)

In the past six months, Aytu Biopharma's stock has trended upwards. Key events impacting the stock include the Q1 Fiscal 2026 Earnings Release on November 13, 2025, the commercial availability of EXXUA™ on December 15, 2025, the Q4 Fiscal 2025 earnings results on September 23, 2025 and the sale of its Consumer Health business in August 2024 to focus on its prescription pharmaceutical segment.

While specific detailed data on demand seasonality for Aytu Biopharma's products and services requires access to specialized platforms, tools are available to analyze AYTU's stock seasonality by displaying mean and median monthly returns to identify patterns.

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics, operating within the Healthcare sector. The company is dedicated to improving patient lives by providing innovative and accessible treatment options, with a particular emphasis on niche markets and prescription drugs. Aytu's portfolio includes prescription products for ADHD, MDD, and pediatric conditions. The company previously offered products through a Consumer Health segment, which was divested in August 2024.

Aytu Biopharma, Inc. is headquartered in Denver, Colorado, United States. The company focuses on commercializing its therapeutics in the United States and internationally. It is actively expanding its geographic reach for its ADHD franchise, including opportunistic growth into new territories, particularly westward. Aytu leverages unique distributors and its RxConnect network of pharmacies to extend its reach into areas without a direct sales force presence.

Aytu Biopharma has demonstrated strong growth, being recognized for the fourth consecutive year on the 2024 Deloitte Technology Fast 500™ list, ranking 380th. This recognition highlights the company's successful repositioning as a growing specialty pharmaceutical company focused on commercializing novel prescription therapeutics and its commitment to operational improvements. The company's strategic focus on its higher-margin Rx Segment and efforts to improve coverage and patient access across its portfolio are expected to drive continued growth.

Aytu Biopharma, Inc. has a significant institutional ownership, with 43 institutional owners holding a total of 3,775,504 shares. Major institutional shareholders include Nantahala Capital Management, LLC, Stonepine Capital Management, LLC, AWM Investment Company, Inc., and Vanguard Group Inc. Armistice Capital LLC is noted as a significant individual/insider shareholder, owning 11.08 million shares, representing 108.74% of the company.